Dakshidin CEO Joins GenBio CEO on Podcast to Discuss Entering 191 Billion Dollar Anti-Inflammatory Market, Their Strategic Partnership and Research Potential
ACCESSWIRE
21 May 2021, 00:05 GMT+10
SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Dakshidin Corp (OTC PINK:DKSC) CEO Chris Haigh and Giles Tilley, Managing Director of GenBio Inc. an early-stage Biotechnology Company joined Stock Day host Everett Jolly for an interview. How did you get involved with GenBio? , Jolly asked Haigh. It was prior to the epidemic to start with, explained Haigh. I was introduced to Giles by a mutual acquaintance who thought that there was a synergy between us, he continued, noting that Dakshidin is in the process of being renamed Whitechapel Holdings . Whitechapel is very involved, and has been for a long time, in the health and wellness space, but completely organic and natural, said Haigh.
Dakshidin CEO Joins GenBio CEO on Podcast to Discuss Entering 191 Billion Dollar Anti-Inflammatory Market, Their Strategic Partnership and Research Potential
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Dakshidin CEO Joins GenBio CEO on Podcast to Discuss Entering 191 Billion Dollar Anti-Inflammatory Market, Their Strategic Partnership and Research Potential
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Dakshidin CEO Joins GenBio CEO on Podcast to Discuss Entering 191 Billion Dollar Anti-Inflammatory Market, Their Strategic Partnership and Research Potential
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
IDenta Corp Reports 2021 First Quarter Financial Results and Shows a 54% Increase in Sales
USA - English
Share this article
HOLLYWOOD, Fla., May 14, 2021 /PRNewswire/
IDenta Corp. (OTCQB: IDTA) is a worldwide leader in the development of Detection Kits to identify Drugs and Explosives and Unique Forensic Products in the Homeland Security Market and Consumer Market. Today IDenta Corp reported its 2021 first quarter financial statement. The revenue was $352,247 for the first quarter of 2021 compared to $227,571 for the same period of 2020. This is a 54% increase in sales.
Mr. Amichai Glattstein, Chief Executive Officer, commented: We are pleased to announce a strong start to 2021 with revenue growth of 54% over the prior year quarter. The company continues to show an increase in sales and invests resources to increase production capacity to keep pace with orders. In addition, the company is investing in building a new infrastructure to create a platform of additional sales ch